Extended Data Fig. 7: Patient ARAF mutations confirm resistance in BRAF- and NRAS-mutant cell lines.
From: ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
a, Confirmation of ARAF-mutant overexpression in doxycycline-inducible cell lines (IPC-298, A375, WM-266-4, MelJuso) treated with doxycycline, assayed by Flag–ARAF western blot. b–e, Cellular viability of IPC-298 (b), A375 (c), WM-266-4 (d), or MelJuso (e) doxycycline-inducible expression of patient derived ARAF mutations (G387N, P462L, G377R) or wild-type treated with belvarafenib for 3 days ± doxycycline. Data are mean ± s.e.m., n = 3 replicates. IC50 values are indicated. f, Confirmation of ARAF double-mutation overexpression in doxycycline-inducible IPC-298 cells treated with doxycycline, assayed by Flag–ARAF western blot. g, Cellular viability of IPC-298 doxycycline-inducible expression of ARAF double mutations treated with belvarafenib for 3 days ± doxycycline. Data are mean ± s.e.m., n = 3 replicates. IC50 values are indicated. h, MAPK signalling in IPC-298 cells transiently transfected with ARAF constructs, treated with serial titration of belvarafenib for 24 h. i, Cellular viability of IPC-298 doxycycline-inducible cells expressing ARAF patient-derived mutations or wild-type ARAF, treated with AZ-628, LXH-254, cobimetinib or GDC-0994 for 3-days ± doxycycline. Data are mean ± s.e.m., n = 3 replicates.
